BioSpace News Archive

ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Aging, demonstrating that inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease resulting in worsening outcomes.

Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October 25, 2023.

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m. ET.

Vanqua Bio announced today that the company will participate in the Leerink Partners Biopharma Private Company Connect, which is being held virtually October 25-26.

Gameto announced that Goldman Sachs is recognizing Gameto CEO and Co-Founder Dr. Dina Radenkovic as one of the Most Exceptional Entrepreneurs of 2023 at its Builders and Innovators Summit in Healdsburg, California.

Complete Genomics, Inc. announced its partnership with Integrated DNA Technologies, a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics’ innovative DNBSEQ™ sequencing platforms.

Novavax, Inc. today announced that Singapore’s Health Sciences Authority (HSA) has granted full approval for Novavax’s prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Alto Neuroscience today announced the appointment of Andrew Dreyfus, former president and CEO of BCBSMA, to the company’s board of directors as an independent board member.